19 results
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
• To assess the effect of lorazepam compared to placebo on stability (Body Sway) in relation to stabilizing subsystems (BalRoom) in healthy elderly.• To assess the effect of haloperidol compared to placebo on stability (Body Sway) in relation to…
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.
Primary objective(s):To evaluate the effect of early haloperidol prophylaxis on the incidence, severity and duration of in-hospital delirium in at-risk patients aged 70 years and over who are acutely admitted to the hospital through the ED, for…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.
To evaluate whether preventive treament with haloperidol lowers the risk for delirium in stroke patients with an increased risk for delirium.
The role of dopamine in bias and disengagement, two mechanisms implicated in visuospatial attention.
To gain insight in the role of the dopaminergic system in two components of visuospatial attention, bias and disengagement.
Firstly, to investigate whether the absolute magnitude of Platelet Inhibition inversely correlates with the number of TCD-detected microemboli during and after CAS in patients who are being pre-treated with either a 300 mg or a 600 mg loading dose…
The primary objective of this study is to demonstrate non-inferiority by pharmacodynamic (PD) analysis of the prasugrel 5-mg maintenance dose (MD) in aspirin-treated subjects <60 kg with stable coronary artery disease (CAD) versus the…
The primary objective of this study is to determine whether clopidogrel + best medical treatment is superior to best medical treatment only in preventing:A) cardiovascular death, MI, stroke, or severe ischemia of the coronary or peripheral arterial…
The current study is designed as a first exploration of this model. The hypothesis is that haloperidol will lead to an amelioration of the *psychotomimetic* effects of the THC-challenge.
The purpose of this study is to investigate the role of dopamine in learning about sexual reward in healthy females. We suppose that repeated associations between a neutral stimulus and sexual stimulation results, through classical conditioning, in…
Primary:To evaluate the efficacy of 0.2 mg/kg/day of clopidogrel versus placebo for the reduction of all-cause mortality and shunt-related morbidity in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary…
In this study we aim to examine the effects of a low dosage of prophylactic haloperidol in patients with an expected ICU length of stay of >1 day. We use two different dosages of haloperidol in this study to compare with placebo. A dosage of…
The objective of the proposed study is to evaluate if results as are written above, are to be extrapolated on high risk patients who underwent vascular surgery. In this group of patients, there is a substantial risk of 15-20% to die in the first…
This study aims to clarify whether the brain dopamine and noradrenaline system underlie the electrocortical responses (event-related potentials) that are sensitive to cues signalling reward and probability, the P200 and P300.
Research questionWill prophylactic administration of haloperidol to patients with a high risk of developing a delirium according to DEMO, reduce the incidence of a delirium? HypothesesProphylactic administration of haloperidol in post-operative…
To assess whether and to what extent dual therapy clopidogrel 75 mg/acetylsalicylic acid 80 mg daily is superior to monotherapy clopidogrel 75 mg daily, in reducing the combined endpoint all-cause death and cardiovascular adverse events after one-…